| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 16.98% | Truist Securities | → $70 | Reiterates | Buy → Buy |
| 08/10/2023 | 20.32% | Guggenheim | $62 → $72 | Maintains | Buy |
| 07/27/2023 | 3.61% | Guggenheim | $59 → $62 | Maintains | Buy |
| 07/21/2023 | 0.27% | Truist Securities | $52 → $60 | Maintains | Buy |
| 05/09/2023 | -1.4% | Guggenheim | $55 → $59 | Maintains | Buy |
| 05/09/2023 | -13.1% | Truist Securities | $50 → $52 | Maintains | Buy |
| 05/09/2023 | -18.11% | Raymond James | $48 → $49 | Maintains | Outperform |
| 05/09/2023 | 0.27% | HC Wainwright & Co. | $53 → $60 | Maintains | Buy |
| 03/13/2023 | -11.43% | HC Wainwright & Co. | $50 → $53 | Maintains | Buy |
| 03/01/2023 | -8.09% | Guggenheim | → $55 | Initiates Coverage On | → Buy |
| 02/21/2023 | -16.44% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 09/07/2022 | -16.44% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 08/09/2022 | -19.79% | Raymond James | $47 → $48 | Maintains | Outperform |
| 03/16/2022 | -21.46% | Raymond James | $65 → $47 | Maintains | Outperform |
| 11/02/2021 | 8.62% | Raymond James | $60 → $65 | Maintains | Outperform |
| 11/02/2021 | 16.98% | Truist Securities | → $70 | Initiates Coverage On | → Buy |
| 05/10/2021 | 0.27% | Raymond James | $40 → $60 | Maintains | Outperform |
| 08/03/2020 | -33.16% | Raymond James | $49 → $40 | Maintains | Outperform |
| 05/08/2020 | -18.11% | Raymond James | $65 → $49 | Maintains | Outperform |
| 05/07/2020 | -33.16% | Cantor Fitzgerald | $78 → $40 | Downgrades | Overweight → Neutral |
| 04/30/2020 | -3.07% | Guggenheim | $62 → $58 | Maintains | Buy |
| 02/28/2020 | 8.62% | Raymond James | $75 → $65 | Maintains | Outperform |
| 11/07/2019 | 25.33% | Raymond James | $82 → $75 | Maintains | Outperform |
| 09/12/2019 | 27.01% | Guggenheim | → $76 | Initiates Coverage On | → Buy |
| 05/10/2019 | 37.03% | Raymond James | $73 → $82 | Downgrades | Strong Buy → Outperform |
| 11/12/2018 | 16.98% | Canaccord Genuity | $75 → $70 | Maintains | Buy |
What is the target price for ANI Pharmaceuticals (ANIP)?
The latest price target for ANI Pharmaceuticals (NASDAQ: ANIP) was reported by Truist Securities on August 21, 2023. The analyst firm set a price target for $70.00 expecting ANIP to rise to within 12 months (a possible 16.98% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ANI Pharmaceuticals (ANIP)?
The latest analyst rating for ANI Pharmaceuticals (NASDAQ: ANIP) was provided by Truist Securities, and ANI Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for ANI Pharmaceuticals (ANIP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ANI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ANI Pharmaceuticals was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
Is the Analyst Rating ANI Pharmaceuticals (ANIP) correct?
While ratings are subjective and will change, the latest ANI Pharmaceuticals (ANIP) rating was a reiterated with a price target of $0.00 to $70.00. The current price ANI Pharmaceuticals (ANIP) is trading at is $59.84, which is within the analyst's predicted range.